A campaign to raise awareness of sepsis in Scotland, combined with the introduction of the latest technology in microbiology, has had a positive impact on the speed of clinical intervention and potential outcomes in the fight against this serious condition, as Janet Young explains. Read the full article here. (Licenced from Pathology in Practice Volume 20, Issue 5, October 2019)
bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical
Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).